Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | APAF1 | O14727 | 2/20 | 0.32 |
| ▸ | UBE2N | P61088 | 2/20 | 0.32 |
| ▸ | IDE | P14735 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | GCK | P35557 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | TDO2 | P48775 | 2/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4234307 | 0.78 | GPBAR1 (0.37) | GAAAPAF1UBE2NIDERECQL | |
| SCHEMBL4222356 | 0.76 | APAF1 (0.33) | APAF1UBE2NIDERECQLNPSR1 | |
| SCHEMBL5623671 | 0.69 | APAF1 (0.34) | APAF1UBE2NIDERECQLNPSR1 | |
| SCHEMBL4228532 | 0.69 | GRM2 (0.36) | GRM2GAAAPAF1UBE2NIDE | |
| SCHEMBL4215795 | 0.68 | KMT2A (0.41) | GAA | |
| SCHEMBL16463136 | 0.68 | P2RX7 (0.51) | — | |
| SCHEMBL4228523 | 0.66 | TRPM8 (0.40) | GRM2APAF1UBE2NIDERECQL | |
| SCHEMBL23888234 | 0.64 | L3MBTL1 (0.46) | GAA | |
| SCHEMBL29869531 | 0.64 | L3MBTL1 (0.46) | GAA | |
| SCHEMBL24468212 | 0.63 | KMT2A (0.46) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090075968-A1 | CETP inhibitors | SAKAKI JUNICHI | 2009-03-19 | — | — | US | disclosed |
| EP-1968941-A1 | PYRIDINYL AMINE DERIVATIVES AS INHIBITORS OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) | Novartis AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007073934-A1 | PYRIDINYL AMINE DERIVATIVES AS INHIBITORS OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) | NOVARTIS AG (CH) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075968-A1 | CETP inhibitors | CETP, PCSK9, MTTP | GRM2 4879/4885RPS6KB1 3567/4885GAA 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.